Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: placebo + pioglitazone (30 mg)
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 389
- Registration Number
- NCT00641043
- Locations
- 🇭🇺
1218.15.36002 Boehringer Ingelheim Investigational Site, Szombathely, Hungary
🇪🇸1218.15.34006 Boehringer Ingelheim Investigational Site, Madrid, Spain
🇬🇷1218.15.30006 Boehringer Ingelheim Investigational Site, Thessaloniki, Greece
Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 33247
- Registration Number
- NCT00638911
Special Survey Long-term Treatment With Tiotropium on COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2014-06-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 385
- Registration Number
- NCT00638183
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site, Yurihonjo, Japan
BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2015-09-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 68
- Registration Number
- NCT00632749
- Locations
- 🇩🇪
1247.3.49004 Boehringer Ingelheim Investigational Site, Freiburg, Germany
🇩🇪1247.3.49007 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇩🇪1247.3.49005 Boehringer Ingelheim Investigational Site, Frankfurt/Main, Germany
Safety and Effectiveness of Spiriva in COPD (Chronic Obstructive Pulmonary Disease) Patients Under the Real Condition of Usual Practice
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2031
- Registration Number
- NCT00624377
- Locations
- 🇨🇳
Boehringer Ingelheim Investigational Site 1, Taipiei, Taiwan
🇨🇳Boehringer Ingelheim Investigational Site 5, Taipiei, Taiwan
🇨🇳Boehringer Ingelheim Investigational Site, Taoyuan, Taiwan
26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 838
- Registration Number
- NCT00624052
- Locations
- 🇪🇸
1235.8.34005 Boehringer Ingelheim Investigational Site, Santa Coloma de Gramanet, Spain
🇪🇸1235.8.34004 Boehringer Ingelheim Investigational Site, Madrid, Spain
🇪🇸1235.8.34001 Boehringer Ingelheim Investigational Site, Jerez de la Frontera (Cádiz), Spain
STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
- Conditions
- Myocardial Infarction
- Interventions
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1899
- Registration Number
- NCT00623623
- Locations
- 🇮🇹
1123.28.39001A Boehringer Ingelheim Investigational Site, Monza, Italy
🇫🇷1123.28.3329A Boehringer Ingelheim Investigational Site, Aubervilliers Cedex, France
🇫🇷1123.28.3329C Boehringer Ingelheim Investigational Site, Aubervilliers Cedex, France
Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mgDrug: Placebo identical to BI 1356 5mg
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1560
- Registration Number
- NCT00622284
- Locations
- 🇺🇸
1218.20.10030 Boehringer Ingelheim Investigational Site, Topeka, Kansas, United States
🇺🇸1218.20.10035 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States
🇺🇸1218.20.10003 Boehringer Ingelheim Investigational Site, Chula Vista, California, United States
RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2014-03-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1878
- Registration Number
- NCT00621855
- Locations
- 🇨🇦
1160.67.11020 Boehringer Ingelheim Investigational Site, Sudbury, Ontario, Canada
🇨🇦1160.67.11018 Boehringer Ingelheim Investigational Site, London, Ontario, Canada
🇧🇪1160.67.32003 Boehringer Ingelheim Investigational Site, Hasselt, Belgium
Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 503
- Registration Number
- NCT00621140
- Locations
- 🇮🇹
1218.16.39004 Boehringer Ingelheim Investigational Site, Catanzaro, Italy
🇮🇹1218.16.39008 Boehringer Ingelheim Investigational Site, Genova, Italy
🇮🇹1218.16.39001 Boehringer Ingelheim Investigational Site, Pisa, Italy